ASH Clinical News ACN_6.4s_SUPP_full_issue | Page 36

The outlook for patients with multiple myeloma is still unfolding. Development in the anti-CD38 class needs to continue. Multiple myeloma remains incurable despite recent therapeutic advances. There’s still a significant need for new treatment options. At Sanofi Genzyme, we’re working to ensure patients can look ahead with newfound hope. Their fi ght is our fi ght. See what’s unfolding at CommittedtoMM.com www.sanofi genzyme.com © 2019 sanofi -aventis U.S. LLC. All rights reserved. SAUS.ONP.19.04.2258